{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:37:03Z","timestamp":1747157823109,"version":"3.40.5"},"reference-count":97,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.clml.2022.04.017","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T06:46:24Z","timestamp":1650609984000},"page":"427-435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["SOHO State of the Art Updates and Next Questions | Management of Most Difficult Cases of Chronic Lymphocytic Leukemia: Relapse After Both BTK and BCL2 Inhibition and Richter Transformation"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5144-6710","authenticated-orcid":false,"given":"John M.","family":"Burke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.04.017_bib0001","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.04.017_bib0002","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.04.017_bib0003","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.04.017_bib0004","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.04.017_bib0005","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.04.017_bib0006","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet Lond Engl"},{"issue":"4","key":"10.1016\/j.clml.2022.04.017_bib0007","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.04.017_bib0008","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.clml.2022.04.017_bib0009","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.04.017_bib0010","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.04.017_bib0011","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.04.017_bib0012","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO Phase III Study","volume":"38","author":"Kater","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.04.017_bib0013","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1182\/blood-2021-148457","article-title":"Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Na\u00efve (TN) Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL)","volume":"138","author":"Tam","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.017_bib0014","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.clml.2022.04.017_bib0015","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.017_bib0016","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.017_bib0017","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","article-title":"Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"30","author":"Fischer","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.clml.2022.04.017_bib0018","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.clml.2022.04.017_bib0019","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.04.017_bib0020","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.04.017_bib0021","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.04.017_bib0022","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3324\/haematol.2018.192328","article-title":"Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2","volume":"103","author":"Barr","year":"2018","journal-title":"Haematologica"},{"issue":"15_suppl","key":"10.1016\/j.clml.2022.04.017_bib0023","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.7523","article-title":"Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"39","author":"Barr","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.04.017_bib0024","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.04.017_bib0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.04.017_bib0026","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/annonc\/mdx031","article-title":"Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients","volume":"28","author":"Mato","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.clml.2022.04.017_bib0027","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/bjh.15802","article-title":"Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis","volume":"185","author":"Eyre","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.04.017_bib0028","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1158\/1078-0432.CCR-19-3815","article-title":"Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy","volume":"26","author":"Mato","year":"2020","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2022.04.017_bib0029","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-123665","article-title":"Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Na\u00efve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)","volume":"134","author":"Brown","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.017_bib0030","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood-2017-01-763003","article-title":"Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax","volume":"129","author":"Anderson","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.017_bib0031","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.04.017_bib0032","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.18.01460","article-title":"Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia","volume":"37","author":"Sharman","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.04.017_bib0033","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","article-title":"The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.017_bib0034","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood.2020007376","article-title":"Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3K\u03b4 inhibitor therapy","volume":"137","author":"Mato","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.04.017_bib0035","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-134783","article-title":"Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Na\u00efve (TN) and Relapsed\/Refractory (R\/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study","volume":"136","author":"Gribben","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.017_bib0036","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2016-05-716977","article-title":"Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience","volume":"128","author":"Mato","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.017_bib0037","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2017-04-775841","article-title":"Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial","volume":"130","author":"Kr\u00e4mer","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.017_bib0038","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1182\/bloodadvances.2020001956","article-title":"Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents","volume":"4","author":"Roeker","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.04.017_bib0039","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/bloodadvances.2020002184","article-title":"Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia","volume":"4","author":"Kim","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.04.017_bib0040","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1182\/blood.2020008502","article-title":"How I treat chronic lymphocytic leukemia after venetoclax","volume":"138","author":"Lew","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.017_bib0041","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1182\/bloodadvances.2021005083","article-title":"Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition","volume":"5","author":"Lew","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.04.017_bib0042","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/bloodadvances.2018030007","article-title":"Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib","volume":"3","author":"Awan","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.04.017_bib0043","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.3324\/haematol.2020.272500","article-title":"Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"106","author":"Rogers","year":"2021","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.04.017_bib0044","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2021-148544","article-title":"Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed\/Refractory B-Cell Malignancies","volume":"138","author":"Shadman","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.017_bib0045","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cmdc.200600221","article-title":"Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase","volume":"2","author":"Pan","year":"2007","journal-title":"ChemMedChem"},{"key":"10.1016\/j.clml.2022.04.017_bib0046","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/jpet.117.242909","article-title":"Acalabrutinib (ACP-196): a covalent bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile","volume":"363","author":"Barf","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clml.2022.04.017_bib0047","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of Zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton's tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.clml.2022.04.017_bib0048","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.04.017_bib0049","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet Lond Engl"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.04.017_bib0050","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood-2021-148672","article-title":"Preliminary Efficacy and Safety of MK-1026, a Non-Covalent Inhibitor of Wild-Type and C481S Mutated Bruton Tyrosine Kinase, in B-Cell Malignancies: A Phase 2 Dose Expansion Study","volume":"138","author":"Woyach","year":"2021","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2022.04.017_bib0051","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-126286","article-title":"Ongoing results of a phase 1B\/2 dose-escalation and cohort-expansion study of the selective, noncovalent, reversible Bruton's tyrosine kinase inhibitor, vecabrutinib, in B-cell malignancies","volume":"134","author":"Allan","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.04.017_bib0052","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood-2021-151073","article-title":"Favorable Modulation of Chimeric Antigen Receptor T Cells Safety and Efficacy By the Non-Covalent BTK Inhibitor Vecabrutinib","volume":"138","author":"Adada","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.04.017_bib0053","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1182\/blood-2021-148827","article-title":"A Phase 1a\/b Dose Escalation Study of the Mutation Agnostic BTK\/FLT3 Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory B-Cell Malignancies","volume":"138","author":"Samaniego","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.04.017_bib0054","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-152811","article-title":"Trial in Progress: Phase 1b Study of Lisaftoclax (APG-2575) As a Single Agent or Combined with Other Therapeutic Agents in Patients with Relapsed and\/or Refractory Chronic Lymphocytic Leukemia (CLL)\/Small Lymphocytic Lymphoma (R\/R CLL\/SLL)","volume":"138","author":"Davids","year":"2021","journal-title":"Blood"},{"issue":"16 Supplement","key":"10.1016\/j.clml.2022.04.017_bib0055","article-title":"Abstract 3077: Preclinical characterization of BGB-11417, a potent and selective Bcl-2 inhibitor with superior antitumor activities in haematological tumor models","volume":"80","author":"Hu","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2022.04.017_bib0056","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor\u2013modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"7897","key":"10.1016\/j.clml.2022.04.017_bib0057","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.clml.2022.04.017_bib0058","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor\u2013modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.04.017_bib0059","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1200\/JCO.19.03237","article-title":"Long-term outcomes from a randomized dose optimization study of chimeric antigen receptor modified T cells in relapsed chronic lymphocytic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.04.017_bib0060","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.017_bib0061","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/ijc.33212","article-title":"Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients","volume":"148","author":"Fan","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2022.04.017_bib0062","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood.2021011597","article-title":"PI3K\u03b4\/\u03b3 inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity","volume":"139","author":"Funk","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2022.04.017_bib0063","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1182\/blood.2021011895","article-title":"Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed\/refractory CLL or SLL","volume":"139","author":"Siddiqi","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.04.017_bib0064","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-140622","article-title":"Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed\/Refractory (R\/R) Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL)","volume":"136","author":"Wierda","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.017_bib0065","first-page":"285","article-title":"Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia","volume":"4","author":"Richter","year":"1928","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clml.2022.04.017_bib0066","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/leu.2016.113","article-title":"Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL","volume":"30","author":"Maurer","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.04.017_bib0067","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bjh.12458","article-title":"Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients","volume":"162","author":"Parikh","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.04.017_bib0068","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2022.04.017_bib0069","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/leu.2017.175","article-title":"Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL\/SLL","volume":"32","author":"Brown","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.04.017_bib0070","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/cncr.30596","article-title":"Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.04.017_bib0071","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/leu.2015.21","article-title":"Diagnostic and prognostic role of PET\/CT in patients with chronic lymphocytic leukemia and progressive disease","volume":"29","author":"Mauro","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.04.017_bib0072","first-page":"1267","article-title":"Detection of Richter's transformation of chronic lymphocytic leukemia by PET\/CT","volume":"47","author":"Bruzzi","year":"2006","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"10.1016\/j.clml.2022.04.017_bib0073","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.017_bib0074","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1084\/jem.20131448","article-title":"Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome","volume":"210","author":"Fabbri","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.clml.2022.04.017_bib0075","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1034\/j.1600-0609.2003.00089.x","article-title":"Molecular differences between small and large cells in patients with chronic lymphocytic leukemia","volume":"71","author":"Lee","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2022.04.017_bib0076","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/ajcp\/104.2.199","article-title":"Trisomy 12 in Richter's transformation of chronic lymphocytic leukemia","volume":"104","author":"Brynes","year":"1995","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2022.04.017_bib0077","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0002-9440(10)64256-3","article-title":"Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large-cell lymphoma (Richter's syndrome)","volume":"161","author":"Be\u00e0","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clml.2022.04.017_bib0078","doi-asserted-by":"crossref","first-page":"E239","DOI":"10.1002\/ajh.23841","article-title":"Poor efficacy and tolerability of R-CHOP in relapsed\/refractory chronic lymphocytic leukemia and Richter transformation","volume":"89","author":"Langerbeins","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.04.017_bib0079","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.15035","article-title":"A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor","volume":"180","author":"Rogers","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.04.017_bib0080","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.clml.2013.03.012","article-title":"Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed\/refractory chronic lymphocytic leukemia or Richter syndrome","volume":"13","author":"Tsimberidou","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.04.017_bib0081","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.clml.2022.04.017_bib0082","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1182\/blood-2014-12-610782","article-title":"The efficacy of ibrutinib in the treatment of Richter syndrome","volume":"125","author":"Tsang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.017_bib0083","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1016\/S2352-3026(21)00305-7","article-title":"Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study","volume":"8","author":"Eyre","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2022.04.017_bib0084","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.04.017_bib0085","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.017_bib0086","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1111\/bjh.16762","article-title":"Pembrolizumab in relapsed or refractory Richter syndrome","volume":"190","author":"Armand","year":"2020","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.04.017_bib0087","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-117526","article-title":"Phase I\/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed\/Refractory CLL and Richter's Transformation","volume":"132","author":"Mato","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.017_bib0088","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1182\/bloodadvances.2020002783","article-title":"Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome","volume":"4","author":"Kittai","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.04.017_bib0089","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.017_bib0090","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.04.017_bib0091","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-138904","article-title":"Safety and Efficacy of CD19-CAR T Cells in Richter\u2019s Transformation after Targeted Therapy for Chronic Lymphocytic Leukemia","volume":"136","author":"Benjamini","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.017_bib0092","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","article-title":"Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation","volume":"24","author":"Tsimberidou","year":"2006","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.clml.2022.04.017_bib0093","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1200\/JCO.2011.37.4108","volume":"30","author":"Cwynarski","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.clml.2022.04.017_bib0094","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/j.clml.2017.10.002","article-title":"Allogeneic hematopoietic cell transplantation for richter syndrome: a single-center experience","volume":"18","author":"Kharfan-Dabaja","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.04.017_bib0095","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.hemonc.2020.05.002","article-title":"Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome: a systematic review and meta-analysis","volume":"14","author":"Aulakh","year":"2021","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.clml.2022.04.017_bib0096","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/bloodadvances.2021004865","article-title":"Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma\u2013type Richter syndrome","volume":"5","author":"Herrera","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.04.017_bib0097","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.3324\/haematol.2021.279033","article-title":"Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation","volume":"106","author":"Kim","year":"2021","journal-title":"Haematologica"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022001306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022001306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T14:01:27Z","timestamp":1682949687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022001306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":97,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2152265022001306"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.04.017","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Management of Most Difficult Cases of Chronic Lymphocytic Leukemia: Relapse After Both BTK and BCL2 Inhibition and Richter Transformation","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}